146 related articles for article (PubMed ID: 19886867)
1. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
2. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
3. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro.
Hägerkvist R; Makeeva N; Elliman S; Welsh N
Cell Biol Int; 2006 Dec; 30(12):1013-7. PubMed ID: 17020808
[TBL] [Abstract][Full Text] [Related]
5. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research.
Sekar N; Li J; Shechter Y
Crit Rev Biochem Mol Biol; 1996 Dec; 31(5-6):339-59. PubMed ID: 8994801
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
Malek R; Davis SN
Expert Opin Investig Drugs; 2016; 25(3):287-96. PubMed ID: 26765364
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes.
Prada PO; Saad MJ
Expert Opin Investig Drugs; 2013 Jun; 22(6):751-63. PubMed ID: 23705634
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity induced by tyrosine kinase inhibitors.
Orphanos GS; Ioannidis GN; Ardavanis AG
Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic effects of electrolyzed reduced water in streptozotocin-induced and genetic diabetic mice.
Kim MJ; Kim HK
Life Sci; 2006 Nov; 79(24):2288-92. PubMed ID: 16945392
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies with imatinib in 2004].
Eckhardt S
Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
[TBL] [Abstract][Full Text] [Related]
12. The importance of beta-cell management in type 2 diabetes.
Standl E
Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
[TBL] [Abstract][Full Text] [Related]
13. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors in cancer therapy.
Madhusudan S; Ganesan TS
Clin Biochem; 2004 Jul; 37(7):618-35. PubMed ID: 15234243
[TBL] [Abstract][Full Text] [Related]
15. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
Louvet C; Szot GL; Lang J; Lee MR; Martinier N; Bollag G; Zhu S; Weiss A; Bluestone JA
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18895-900. PubMed ID: 19015530
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
18. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
19. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.
Chintalgattu V; Patel SS; Khakoo AY
Hematol Oncol Clin North Am; 2009 Feb; 23(1):97-107, viii-ix. PubMed ID: 19248973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
